Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
AMLBiomarker-Driven Lung CancerBone Marrow & SCTBTK Inhibitors: In-FocusCAR T-Cell TherapyChronic Lymphocytic LeukemiaEGFR-Positive Lung CancerEndometrial CancerFollicular LymphomaHCCLung CancerMantle Cell LymphomaMPNsMultiple MyelomaRenal Cell CarcinomaSmall Cell Lung CancerThyroid Cancers
Clinical Focus
View MoreBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancersGynecologic CancersHead & Neck CancersHematologyLeukemiasLung CancerLymphomasMelanomaSarcomaSkin CancersThyroid Cancers
Spotlight
View MoreCase Based Peer PerspectivesCase-Based Roundtable SeriesClinical TrialsPodcastsPrecision MedicineSpecial Reports
NEWS
All NewsClinical FocusSpecial Reports
CONFERENCES
Conference CoverageConference Listing
MEDIA
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPodcastsPrecision Medicine
PUBLICATIONS
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
eNewsletter
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Advertisement
Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Bone Marrow & SCT
  • BTK Inhibitors: In-Focus
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR-Positive Lung Cancer
  • Endometrial Cancer
  • Follicular Lymphoma
  • HCC
  • Lung Cancer
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
SpotlightSee All >
  • Case Based Peer Perspectives
  • Case-Based Roundtable Series
  • Clinical Trials
  • Podcasts
  • Precision Medicine
  • Special Reports
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, MD, gives a comprehensive background and analysis on the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus versus sunitinib in the treatment of advanced renal cell carcinoma.

EP. 1: Current Therapies for Advanced RCC: Options and Challenges

June 29th 2021

Robert J. Motzer, MD, gives a background on the current first-line therapy options for advanced renal cell carcinoma, including challenges and unmet needs.

EP. 2: Key Efficacy and Safety Findings from the CLEAR Trial

June 29th 2021

Dr Robert J. Motzer introduces data from the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus for the treatment of advanced renal cell carcinoma.

EP. 3: Impact of the CLEAR Trial on Clinical Practice

June 29th 2021

An expert explains the impact of the CLEAR trial on clinical practice and reviews NCCN guidelines for the management of advanced renal cell carcinoma.

EP. 4: Updates on CLEAR from ASCO 2021

June 29th 2021

Dr Motzer discusses data from the CLEAR trial that were presented at ASCO 2021.

EP. 5: The Future of Therapy for Advanced RCC

June 29th 2021

Robert J. Motzer, MD, shares his insights on the future of treatment for advanced renal cell carcinoma.

Advertisement
Advertisement